Table 2.
Study | Patient population | Therapy | Duration (wk) | SVR | Comments |
ION-1 | First-line therapy | SOF + LDV | 12 | 99% | |
SOF + LDV + R | 12 | 97% | |||
SOF + LDV | 24 | 98% | |||
SOF + LDV + R | 24 | 99% | |||
ION-2 | Re-therapy | SOF + LDV | 12 | 94% | 86% cirrhotic |
SOF + LDV + R | 12 | 96% | 82% cirrhotic | ||
SOF + LDV | 24 | 99% | 100% cirrhotic | ||
SOF + LDV + R | 24 | 99% | 86% cirrhotic | ||
ION-3 | First-line therapy | SOF + LDV | 8 | 94% | Only non-cirrhotic |
SOF + LDV + R | 8 | 93% | Only non-cirrhotic | ||
SOF + LDV | 12 | 95% | Only non-cirrhotic |
SOF: Sofosbuvir; LDV: Ledipasvir; R: Ribavirin; SVR: Sustained virological response.